Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - linezolid - film-coated tablet - 600 milligram(s) - other antibacterials; linezolid - antibacterials for systemic use, other antibacterials - linezolid krka is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid krka is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; magnesium stearate; maize starch; sodium starch glycollate type a; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate type a; hyprolose; microcrystalline cellulose; maize starch; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3000 - linezolid ca is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,linezolid ca is active against gram-positive bacteria only. ,linezolid ca has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram- negative pathogen is documented or suspected.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - linezolid - film-coated tablet - linezolid 600 mg - antibacterials for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - linezolid - film-coated tablet - 600 milligram(s) - other antibacterials; linezolid

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - linezolid (form iii) - film-coated tablet - 600 milligram(s) - other antibacterials; linezolid

Ireland - English - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - linezolid - film-coated tablet - 600 milligram(s) - other antibacterials; linezolid

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - linezolid - film-coated tablet - 600 milligram(s) - other antibacterials; linezolid

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - linezolid - film-coated tablet - 600 milligram(s) - other antibacterials; linezolid

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - linezolid, quantity: 600 mg - tablet, film coated - excipient ingredients: silicon dioxide; sodium stearylfumarate; copovidone; mannitol; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 400 - pharmacor linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species.,pharmacor linezolid is active against gram-positive bacteria only. pharmacor linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.